Jazz Pharmaceuticals is actively exploring mergers and acquisitions of different sizes as it concludes its legal battles over the patent for Epidiolex, a medication used to treat seizures.
During Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd quickly highlighted the company’s interest in making new deals. Some of the drugs they are known for include Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia.